Pexastimogene Devacirepvec (Pexa Vec)

Phase 3Biologic

Pexastimogene Devacirepvec (Pexa Vec) is one of 71 biologic programs targeting Hepatocellular Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Hepatocellular CarcinomaPhase 3

Active, not recruiting

Renal Cell CarcinomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Pexastimogene Devacirepvec (Pexa Vec)

SSillaJen, Inc.

Phase 3

2 2

Sovaldi

Gilead

Preclinical

1 3

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Preclinical

16 4

Doptelet

AAkarx

Preclinical

1 5

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 6

Vermox

WWim Janssens

Preclinical

1 7

Opdivo

Bristol-Myers Squibb

Preclinical

2 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 9

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

5 10

Alcohol

Astellas

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone

Completed·SSillaJen, Inc.·Phase 3·NCT02562755·459 enrolled

A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

Terminated·TTransgene·Phase 1/2·NCT03071094·14 enrolled

Renal Cell Carcinoma1 trial

A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Active, not recruiting·SSillaJen, Inc.·Phase 1/2·NCT03294083·89 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Pexastimogene Devacirepvec (Pexa Vec). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pexastimogene Devacirepvec (Pexa Vec) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pexastimogene Devacirepvec (Pexa Vec). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SillaJen, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: SSillaJen, Inc.

Pexastimogene Devacirepvec (Pexa Vec)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

Renal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News